End-of-day quote
Taipei Exchange
06:00:00 2024-07-09 pm EDT
|
5-day change
|
1st Jan Change
|
66
TWD
|
+2.17%
|
|
0.00%
|
-4.90%
|
Fiscal Period: December |
2022
|
2023
|
---|
Capitalization
1 |
-
|
3,456
|
Enterprise Value (EV)
1 |
-
|
2,320
|
P/E ratio
|
-147
x
|
-92.5
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
-
|
362,885,342
x
|
EV / Revenue
|
-
|
243,556,699
x
|
EV / EBITDA
|
-
|
-37.4
x
|
EV / FCF
|
-
|
-72,937,585
x
|
FCF Yield
|
-
|
-0%
|
Price to Book
|
2.68
x
|
3.04
x
|
Nbr of stocks (in thousands)
|
-
|
49,800
|
Reference price
2 |
63.20
|
69.40
|
Announcement Date
|
4/21/23
|
4/19/24
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
9.524
|
EBITDA
1 |
-11.22
|
-18.07
|
-61.97
|
EBIT
1 |
-11.5
|
-18.61
|
-62.68
|
Operating Margin
|
-
|
-
|
-658.16%
|
Earnings before Tax (EBT)
1 |
-11.24
|
-21.82
|
-34.94
|
Net income
1 |
-11.24
|
-19.54
|
-37.16
|
Net margin
|
-
|
-
|
-390.22%
|
EPS
2 |
-0.6133
|
-0.4304
|
-0.7500
|
Free Cash Flow
|
-
|
-14.29
|
-31.8
|
FCF margin
|
-
|
-
|
-333.92%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
4/21/23
|
4/21/23
|
4/19/24
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
Net Cash position
1 |
904
|
1,165
|
1,136
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-14.3
|
-31.8
|
ROE (net income / shareholders' equity)
|
-
|
-1.88%
|
-3.22%
|
ROA (Net income/ Total Assets)
|
-
|
-1.11%
|
-3.35%
|
Assets
1 |
-
|
1,755
|
1,109
|
Book Value Per Share
2 |
49.10
|
23.60
|
22.80
|
Cash Flow per Share
2 |
44.70
|
7.490
|
2.050
|
Capex
1 |
2.25
|
0.48
|
0.07
|
Capex / Sales
|
-
|
-
|
0.71%
|
Announcement Date
|
4/21/23
|
4/21/23
|
4/19/24
|
|
1st Jan change
|
Capi.
|
---|
| -4.90% | 101M | | +18.09% | 45.01B | | +46.56% | 40.96B | | -8.38% | 38.62B | | +34.66% | 32.6B | | -8.34% | 27.49B | | +16.10% | 27.17B | | +49.73% | 14.61B | | +36.71% | 12.95B | | -6.60% | 11.36B |
Other Biotechnology & Medical Research
|